Roche News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

14.07.20	ENSPRYNG® (Satralizumab) von Roche in der Schweiz zur Behandlung der Neuromyelitis-Optica-Spektrum-Erkrankungen (NMOSD) zugelassen (GlobeNewswire)
13.07.20	New data from phase IIIb study reinforces safety profile of Roche’s Hemlibra in people with haemophilia A (GlobeNewswire)
13.07.20	Roche provides update on Phase III study of Tecentriq in women with advanced stage ovarian cancer (GlobeNewswire)
29.06.20	FDA approves Roche’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for HER2-positive breast cancer (GlobeNewswire)
29.06.20	Roche announces new data at the ISTH 2020 Congress, demonstrating ongoing commitment to advancing care for people with haemophilia A (GlobeNewswire)
26.06.20	Roche improves speed and accuracy of non-small cell lung cancer diagnosis with launch of automated digital pathology algorithm (GlobeNewswire)
19.06.20	Roche’s IPATential150 study evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone met one of its co-primary endpoints (GlobeNewswire)
18.06.20	Roche’s Tecentriq in combination with chemotherapy (including Abraxane) meets primary endpoint of improved pathological complete response, regardless of PD-L1 status, as initial treatment for people w (GlobeNewswire)
13.06.20	Positive phase III results for Venclexta/Venclyxto combination in acute myeloid leukaemia presented at EHA 2020 (GlobeNewswire)
12.06.20	Roche announces 2-year risdiplam data from SUNFISH and new data from JEWELFISH in infants, children and adults with spinal muscular atrophy (SMA) (GlobeNewswire)
04.06.20	Roche’s Elecsys IL-6 test receives FDA Emergency Use Authorisation to help in identifying patients at high risk of severe inflammatory response (GlobeNewswire)
02.06.20	FDA approves Roche’s Tecentriq in combination with Avastin for people with the most common form of liver cancer (GlobeNewswire)
29.05.20	CHMP recommends EU approval of Roche’s Rozlytrek for people with NTRK fusion-positive solid tumours and for people with ROS1-positive, advanced non-small cell lung cancer (GlobeNewswire)
29.05.20	Updated data demonstrate Roche’s Alecensa increases overall survival rate for people with ALK-positive non-small cell lung cancer (GlobeNewswire)
28.05.20	Roche’s OCREVUS (ocrelizumab) shorter 2-hour infusion time approved in Europe (GlobeNewswire)
28.05.20	Roche initiates phase III clinical trial of Actemra/RoActemra plus remdesivir in hospitalised patients with severe COVID-19 pneumonia (GlobeNewswire)
27.05.20	Roche’s Port Delivery System with ranibizumab shows positive phase III results in neovascular age-related macular degeneration (GlobeNewswire)
22.05.20	Roche acquires Stratos Genomics to further develop DNA based sequencing for diagnostic use (GlobeNewswire)
22.05.20	New longer-term data reinforce safety of Roche’s satralizumab in adults and adolescents with neuromyelitis optica spectrum disorder (GlobeNewswire)
19.05.20	FDA approves Roche’s Tecentriq as a first-line monotherapy for certain people with metastatic non-small cell lung cancer (GlobeNewswire)
15.05.20	Roche launches new blood gas digital solution designed to improve patient care (GlobeNewswire)
14.05.20	Roche to present first clinical data on novel anti-TIGIT cancer immunotherapy tiragolumab at ASCO (GlobeNewswire)
11.05.20	A formative figure in the company's history: Roche Honorary Chairman Fritz Gerber dies at the age of 91 (GlobeNewswire)
11.05.20	Prägende Persönlichkeit in der Firmengeschichte: Roche Ehrenpräsident Fritz Gerber im Alter von 91 Jahren verstorben (GlobeNewswire)
11.05.20	Wechsel in der erweiterten Konzernleitung von Roche (GlobeNewswire)
11.05.20	Changes to the Roche Enlarged Corporate Executive Committee (GlobeNewswire)
07.05.20	New data at the ASCO20 Virtual Scientific Program reflects Roche’s commitment to accelerating progress in cancer care (GlobeNewswire)
03.05.20	Roche’s COVID-19 antibody test receives FDA Emergency Use Authorization and is available in markets accepting the CE mark (GlobeNewswire)
28.04.20	New 6-year data for Roche’s OCREVUS (ocrelizumab) show earlier treatment initiation nearly halves risk of needing walking aid in relapsing multiple sclerosis (GlobeNewswire)
28.04.20	Roche’s risdiplam shows significant improvement in survival and motor milestones in infants with Type 1 spinal muscular atrophy (SMA) (GlobeNewswire)
22.04.20	First quarter with 2% growth in Swiss francs, 7%[1] at constant exchange rates (GlobeNewswire)
22.04.20	Erstes Quartal mit Wachstum von 2% in Schweizer Franken; 7%[1] zu konstanten Wechselkursen (GlobeNewswire)
21.04.20	Roche receives FDA approval for cobas HPV test for use on the cobas 6800/8800 Systems to identify women at risk for cervical cancer (GlobeNewswire)
20.04.20	US FDA and EMA accept applications for Roche’s OCREVUS (ocrelizumab) shorter 2-hour infusion time (GlobeNewswire)
17.04.20	Roche develops new serology test to detect COVID-19 antibodies (GlobeNewswire)
07.04.20	Roche provides regulatory update on risdiplam for the treatment of spinal muscular atrophy (SMA) (GlobeNewswire)
24.03.20	Roche response to COVID-19 pandemic (GlobeNewswire)
23.03.20	Roche announces Venclexta/Venclyxto combination improved overall survival in people with previously untreated acute myeloid leukaemia (GlobeNewswire)
19.03.20	Roche initiates Phase III clinical trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 pneumonia (GlobeNewswire)
17.03.20	Roche Generalversammlung 2020 (GlobeNewswire)
17.03.20	Roche Annual General Meeting 2020 (GlobeNewswire)
16.03.20	Roche Annual General Meeting 2020: Voting will take place by independent proxy. Participation on site is neither possible nor permitted by Federal Council ordinance (GlobeNewswire)
16.03.20	Roche Generalversammlung 2020: Abstimmung durch die unabhängige Stimmrechtsvertreterin. Teilnahme vor Ort ist nach Verordnung des Bundesrates weder möglich noch erlaubt (GlobeNewswire)
14.03.20	Roche Annual General Meeting 2020 to take place under special conditions set by the authorities - electronic voting strongly recommended (GlobeNewswire)
14.03.20	Generalversammlung 2020 findet unter behördlichen Auflagen statt – elektronische Stimmabgabe dringend empfohlen (GlobeNewswire)
13.03.20	Roche’s cobas SARS-CoV-2 Test to detect novel coronavirus receives FDA Emergency Use Authorization and is available in markets accepting the CE mark (GlobeNewswire)
12.03.20	European Commission approves Venclyxto plus Gazyvaro for adults with previously untreated chronic lymphocytic leukaemia (GlobeNewswire)
11.03.20	Roche receives FDA approval for CINtec PLUS Cytology test to aid clinicians in improving cervical cancer prevention (GlobeNewswire)
04.03.20	FDA grants Breakthrough Device Designation for Roche's Elecsys GALAD score to support earlier diagnosis of hepatocellular carcinoma (GlobeNewswire)
25.02.20	FDA accepts Roche’s Biologics License Application for fixed-dose subcutaneous combination of Perjeta and Herceptin for HER2-positive breast cancer (GlobeNewswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

22.11.24		Dow Jones aktuell: Dow Jones zum Ende des Freitagshandels in der Gewinnzone
22.11.24		Freundlicher Handel in New York: Dow Jones präsentiert sich am Freitagnachmittag fester
22.11.24		Börse New York in Grün: Dow Jones bewegt sich am Mittag im Plus
22.11.24		Freundlicher Handel: Börsianer lassen SPI schlussendlich steigen
22.11.24		Zuversicht in London: FTSE 100 beendet die Freitagssitzung in der Gewinnzone
22.11.24		Handel in Frankfurt: TecDAX letztendlich in Grün